Open AccessInhibitory Potential of Combination of Macrolide Antibiotic with Conventional Chemotherapeutic Agent Sorafenib on Growth Rate of Cancer Cell Population
Author(s) -
Dabeeran Zehra,
Shumaila Usman,
Kauser Ismail,
Syed Saud Hasan,
Urooj Zafar,
Syed Faizan Ali Rizvi,
Nabila Rasheed
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i47b33124
Subject(s) - sorafenib , repurposing , pharmacology , azithromycin , medicine , antibiotics , antimicrobial , drug , adverse effect , biology , cancer research , microbiology and biotechnology , ecology , hepatocellular carcinoma
Over the past few years great progress has been achieved in anticancer therapy, but development of resistance and unavoidable side effects have incapacitated these fulfilments. Keeping in view this demanding condition, numerous drugs with unique antitumor mechanisms are under investigations including antimicrobials which have been shown to possess anti-inflammatory, immunomodulatory and cytotoxic effects. In this regard, both conventional and novel antimicrobials are being studied to explore their anticancer potential along with underlying mechanisms which may render them as effective anticancer drugs in near future. Moreover, the new approach of drug repurposing is also being encouraged especially in cancers in order to reduce cost and limit adverse effects. In recent times a cumulative number of studies have laid stress upon the antitumor properties of antimicrobials. Consequently, this study has been conducted to see comparative inhibitory effect of Sorafenib and its combination with a macrolide antibiotic Azithromycin on growth rate HepG2 cell line.